Objective

To evaluate if cannabis dose recorded as standard joint unit (SJU) consumed before admission and other related factors have an influence on psychiatric inpatient's symptom severity and clinical outcomes.

Methods

Cross-sectional study in an acute psychiatric inpatient unit including 106 individuals. Quantity of cannabis was measured as SJU and symptoms severity through the Brief Psychiatric Rating Scale (BPRS). Secondary outcomes (e.g. length of stay) were also assessed. Bivariate analyses and multivariate analyses were performed to determine the effect of SJU consumed before admission on measures of clinical severity.

Results

Point prevalence of cannabis use before admission was 25.5%. Mean BPRS score was 55.8 (SD = 16.1); and 62.9 (SD = 11.1) among cannabis users. A low degree positive correlation between SJU consumed the week before admission and BPRS score (r_s = 0.28, p = 0.03) was found. In the multivariate analyses both main diagnostic group, Schizophrenia and other psychotic disorders vs. others (Bipolar and Unipolar Affective Disorders and Addictive disorders) (B = 8.327; 95% CI 4.976–11.677) and need of PRN (“pre re nata” or when necessary) administration of antipsychotics and benzodiazepines (B = 12.13; 95% CI 6.868–17.393) were significant predictors, both increasing BPRS score.

Conclusions

The study did not find a correlation between SJU consumed last week and psychiatric severity. On the other hand, individuals with psychotic disorders reported a higher prevalence of cannabis use the week before admission and displayed higher BPRS scores, which points to the need for the development of tailored interventions for high-risk groups. The SJU is a useful quantification tool suitable for further clinical research.

中文翻译：

---

大麻使用入院前的一周作为严重程度的指标。

目的

为了评估入院前食用的记录为标准关节单位（SJU）的大麻剂量和其他相关因素是否对精神病住院患者的症状严重程度和临床结果产生影响。

方法

横断面研究在一个急性精神科住院病房中，包括106个人。通过简明精神病评定量表（BPRS）将大麻的数量作为SJU和症状严重程度进行测量。还评估了次要结局（例如住院时间）。进行双因素分析和多因素分析，以确定入院前服用的SJU对临床严重程度的影响。

结果

入院前使用大麻的点盛行率为25.5％。BPRS平均得分为55.8（SD = 16.1）; 大麻使用者中为62.9（SD = 11.1）。发现入院前一周食用的SJU与BPRS评分之间呈低度正相关（r _s  = 0.28，p = 0.03）。在多变量分析中，主要诊断组，精神分裂症和其他精神病性疾病与其他疾病（双相性和单相性情感障碍和上瘾性疾病）（B = 8.327； 95％CI 4.976-11.677）和是否需要PRN（“ pre nata”或必要时）服用抗精神病药和苯二氮卓类药物（B = 12.13； 95％CI 6.868–17.393）是重要的预测指标，均可提高BPRS评分。

结论

该研究未发现上周服用的SJU与精神病严重程度之间存在相关性。另一方面，精神病患者在入院前一周使用大麻的患病率较高，并且显示出较高的BPRS评分，这表明有必要针对高风险人群制定量身定制的干预措施。SJU是适用于进一步临床研究的有用的定量工具。